Primary Site >> Colorectal Cancer
Gene >> ERBB2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Protooncogene abnormalities in colon cancers and adenomatous polyps. PMID: 3557013 |
Ref: Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. PMID: 3345525 |
Ref: Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. PMID: 1968437 Ref: Correlation between the presence of microvilli and the growth or metastatic potential of tumor cells. PMID: 1977729 Ref: c-erbB-2 oncoprotein expression in primary human tumors. PMID: 2403483 |
Ref: Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors. PMID: 1680897 Ref: Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues. PMID: 1726578 Ref: [DNA content and c-erbB-2 oncoprotein expression in hepatic metastases from colorectal carcinoma--in relation to clinicopathologic findings and prognosis]. PMID: 1961185 Ref: Enhanced expression of oncogene-encoded mRNA in a rat model of colon cancer. PMID: 2012108 |
Ref: Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. PMID: 1285215 Ref: [Expression of c-erbB-2 protein and vessel invasion in colorectal cancer]. PMID: 1346087 Ref: Human c-erbB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy. PMID: 1347516 Ref: Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR. PMID: 1349430 Ref: Tumor-specific methylation patterns of erbB2 (HER2/neu) sequences in gastro-intestinal cancer. PMID: 1352439 Ref: c-erbB-2/neu in colorectal carcinoma: a potential prognostic value? PMID: 1359899 Ref: Oncogenesis in ovarian cancer. PMID: 1502889 Ref: Detection of transforming oncogenes in rat colon tumors induced by direct perfusion with N-methyl-N-nitrosourea. PMID: 1730134 Ref: Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. PMID: 1741162 |
Ref: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. PMID: 7688814 Ref: HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus. PMID: 7904538 Ref: Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease. PMID: 8099272 |
Ref: Serum c-erbB-2 oncoprotein in the diagnosis of gastric cancer in comparison with CA 19-9, CEA, TPA, CA 125 and AFP. PMID: 7525029 Ref: [Metastasis-related genes]. PMID: 7526801 Ref: Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. PMID: 7868086 |
Ref: Contribution of molecular oncology in the detection of colorectal carcinomas. PMID: 7491839 Ref: Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. PMID: 7579815 Ref: c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. PMID: 7612263 Ref: In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. PMID: 7653991 Ref: Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. PMID: 7797556 Ref: [Rearrangement of the c-erbB2 oncogene--analysis of the gastrocolic carcinoma]. PMID: 7884965 Ref: Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study. PMID: 8669884 |
Ref: Polynucleotide-mediated immunization therapy of cancer. PMID: 8607023 Ref: nm23 expression in advanced and borderline ovarian carcinoma. PMID: 8702236 Ref: Modulation of colon tumor oncogene expression by cancer patient-derived lipids. PMID: 8841466 Ref: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. PMID: 8874347 Ref: Higher expression of oncoproteins c-myc, c-erb B-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. PMID: 8915491 Ref: [Relations between p53 and p185 expression and prognosis of patients with colon cancers]. PMID: 9387311 |
Ref: The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. PMID: 9097992 Ref: Expression of growth factor receptors is not a prognostic indicator in young patients with colorectal cancer. PMID: 9114679 Ref: Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. PMID: 9136822 Ref: Overexpression of c-erbB-2 mRNA and/or c-neu oncoprotein is a predictor for metastases from colorectal cancer. PMID: 9137444 Ref: Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. PMID: 9143415 Ref: Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy. PMID: 9212243 Ref: Isolation of human anti-c-erbB-2 Fabs from a lymph node-derived phage display library. PMID: 9218840 Ref: Molecular genetics of small bowel cancer. PMID: 9298583 Ref: Common patterns of genetic evolution in human solid tumors. PMID: 9298807 Ref: Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. PMID: 9337347 Ref: ErbB kinases and NDF signaling in human prostate cancer cells. PMID: 9400997 Ref: In vivo overexpression of c-erbB-2 oncoprotein in xenografts of mice implanted with human colon cancer lines. PMID: 9413188 Ref: Clinical experience with CD64-directed immunotherapy. An overview. PMID: 9435876 Ref: Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. PMID: 9444956 Ref: Biomarkers for predicting response to regional chemo-immunotherapy in liver metastases from colorectal carcinoma. PMID: 9637342 |
Ref: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. PMID: 9485028 Ref: Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. PMID: 9522212 Ref: Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. PMID: 9613457 Ref: Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. PMID: 9712416 Ref: [Expression of CD44 variant v6 in breast carcinoma and its relationship with other parameters of tumor biology]. PMID: 9732832 Ref: [Dysfunction of E-cadherin-catenin system in invasion and metastasis of colorectal cancer]. PMID: 9742518 Ref: Determination of p185 and adenylosuccinate lyase (ASL) activity in preneoplastic colon lesions and intestinal mucosa of human subjects. PMID: 9812171 Ref: Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. PMID: 9829729 Ref: [Expression and significance of p53, c-erbB2, CEA proteins in colorectal adenoma and carcinoma]. PMID: 10681823 Ref: [Multivariate analysis of clinicopathological and immunohistochemical factors in colorectal carcinomas]. PMID: 11244942 |
Ref: Regulation of cyclooxygenase-2 pathway by HER2 receptor. PMID: 9927187 Ref: Breast cancer imaging with radiolabeled antibodies. PMID: 9990682 Ref: KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. PMID: 10383157 Ref: Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. PMID: 10408800 Ref: Protein markers in colorectal cancer: predictors of liver metastasis. PMID: 10450731 Ref: Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices. PMID: 10470163 Ref: Comparative tyrosine-kinase profiles in colorectal cancers: enhanced arg expression in carcinoma as compared with adenoma and normal mucosa. PMID: 10521789 Ref: Altered midline axon pathways and ectopic neurons in the developing hypothalamus of netrin-1- and DCC-deficient mice. PMID: 10559399 Ref: Prognostic evaluation of metallothionein expression in human colorectal neoplasms. PMID: 10711249 Ref: Current Status and Perspectives in Cancer Chemotherapy. PMID: 11091728 |
Ref: Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer. PMID: 10644313 Ref: Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. PMID: 10655513 Ref: Characterization of a repressor element and a juxtaposed tissue-restricted activator element located on the distal neu gene promoter. PMID: 10692468 Ref: Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. PMID: 10709098 Ref: Different expression of some molecular markers in sporadic cancer of the left and right colon. PMID: 10958329 Ref: The DCC protein expression in breast carcinoma. PMID: 10969518 Ref: Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. PMID: 10987297 Ref: T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens. PMID: 11093821 Ref: C-erbB-2 oncoprotein content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance. PMID: 11729856 |
Ref: Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. PMID: 11349216 Ref: Expression of p185 and p53 in benign and malignant colorectal lesions. PMID: 11352401 Ref: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. PMID: 11375952 Ref: [Genetic changes in liver metastasis of colorectal cancer and their clinical application]. PMID: 11393998 Ref: [Colorectal carcinoma in Cronkhite-Canada syndrome]. PMID: 11413916 Ref: The HER-2/neu oncogene in tumors of the gastrointestinal tract. PMID: 11458821 Ref: Serous tumors of low malignant potential of the ovary-molecular pathology: part 2. PMID: 11469685 Ref: [Activation of K-ras and c-erbB-2 protooncogenes in human colonic adenocarcinomas]. PMID: 11471321 Ref: Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations. PMID: 11507242 Ref: Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. PMID: 11571982 Ref: The role of HER2 in angiogenesis. PMID: 11706393 Ref: Surrogate markers of response to cancer immunotherapy. PMID: 11727526 Ref: [Expression level of c-erbB-2 protein correlates with the prognosis of patients with colorectal cancer]. PMID: 11783020 |
Ref: Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. PMID: 11791178 Ref: Beta-catenin--a linchpin in colorectal carcinogenesis? PMID: 11839557 Ref: c-erbB-2 is not a major factor in the development of colorectal cancer. PMID: 11870539 Ref: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. PMID: 12008194 Ref: Current concepts in immunotherapy for the treatment of colorectal cancer. PMID: 12018689 Ref: The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer. PMID: 12074327 Ref: Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. PMID: 12100028 Ref: Fighting colorectal cancer: molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians. PMID: 12196377 Ref: Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. PMID: 12198768 Ref: Cellular immunity to the Her-2/neu protooncogene. PMID: 12374283 |
Ref: Clinicopathologic characteristics and prognoses of gastric cancer in patients with a positive familial history of cancer. PMID: 12488704 Ref: Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. PMID: 12571082 Ref: Integrin alpha v, c-erbB2 and DNA ploidy in lung metastases from colorectal cancer. PMID: 12629984 Ref: Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. PMID: 12673683 Ref: Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. PMID: 12748185 Ref: HER 2/neu expression and gene amplification in colon cancer. PMID: 12767065 Ref: [Overexpression of c-erbB-2 and hypoexpression of nm23 relating to poor prognosis of colorectal carcinoma]. PMID: 12839671 Ref: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? PMID: 12853343 Ref: Targeted therapy in non-small cell lung cancer: myth or reality. PMID: 12867056 Ref: Immunohistological study of NM 23 and C-erbB-2 expression in primary tumor and metastases of colorectal adenocarcinoma. PMID: 12910292 Ref: Serum levels of c-erbb-2 correlate with advanced stage and liver metastasis in colorectal cancer. PMID: 12943051 Ref: Natural T cell immunity against cancer. PMID: 14555498 Ref: COX-2 inhibitors for the prevention of breast cancer. PMID: 14587862 Ref: An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer. PMID: 14633326 Ref: [Expression of nm23 and c-erbB-2 proteins in cells of primary colorectal cancer and its metastases]. PMID: 14664140 Ref: Recent advances of molecular targeted agents: opportunities for imaging. PMID: 14688462 Ref: Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. PMID: 14703062 Ref: [Effect of learning about the human genome on the development of pathology]. PMID: 14974156 Ref: Monoclonal antibodies in human cancer. PMID: 14988743 |
Ref: Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. PMID: 14685781 Ref: HER2 and COX2 expression in human prostate cancer. PMID: 14687789 Ref: HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. PMID: 14696118 Ref: Multiple biomarkers of colorectal tumor in a differential diagnosis model: a quantitative study. PMID: 14760775 Ref: Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with epstein-barr virus-negative carcinoma. PMID: 15014022 Ref: Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. PMID: 15059917 Ref: [Report of the National Oncology Research and Developement Consortium, 2003]. PMID: 15105900 Ref: Genetic and pathologic significance of 1p, 17p, and 18q aneusomy and the ERBB2 gene in colorectal cancer and related normal colonic mucosa. PMID: 15120910 Ref: The ErbB/HER receptor protein-tyrosine kinases and cancer. PMID: 15158434 Ref: Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays. PMID: 15163022 Ref: Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. PMID: 15228443 Ref: Prognostic significance of the p185 protein in colorectal cancer. PMID: 15255019 Ref: [Clinical significance of HER-2/neu expression in colon cancer]. PMID: 15385723 Ref: K-RAS point mutation, and amplification of C-MYC and C-ERBB2 in colon adenocarcinoma. PMID: 15493579 Ref: Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. PMID: 15585615 Ref: Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. PMID: 15613459 Ref: Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. PMID: 15641483 Ref: [Antibodies against cancer]. PMID: 15710074 Ref: (99m)Tc-Cys-Gly-Gly-Affibody ZHER2:342 PMID: 20641196 Ref: (111)In-Benzyl-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-ZHER2:342 PMID: 20641264 Ref: BODIPY-FL-neutravidin-biotin-Cetuximab PMID: 20641313 Ref: Trastuzumab-manganese-doped iron oxide nanoparticles PMID: 20641351 Ref: (111)In-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid- Affibody ZHER2:342-pep2 PMID: 20641379 Ref: Cy5.5-Trastuzumab PMID: 20641392 Ref: (111)In-Diethylenetriamine pentaacetic acid-pertuzumab PMID: 20641430 Ref: (111)In-CHX-A"-diethylenepentaacetic acid-Affibody ZHER2:2395-Cys PMID: 20641462 Ref: Trastuzumab-rhodamine green PMID: 20641468 Ref: (111)In-CHX-A"-Diethylenetriamine pentaacetic acid-(ZEGFR:955)2 PMID: 20641502 Ref: (111)In-Benzyl-diethylenetriaminepentaacetic acid-ZHER2:342 PMID: 20641524 Ref: [O-(11)C-methyl]4-N-(3-Bromoanilino)-6,7-dimethoxyquinazoline PMID: 20641571 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-cetuximab PMID: 20641633 Ref: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-Epidermal growth factor PMID: 20641634 Ref: (111)In-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-AB.Fab4D5 PMID: 20641705 Ref: Quantum dot-trastuzumab PMID: 20641720 Ref: (99m)Tc-Affibody ZHER2:2395-Cys PMID: 20641788 Ref: IRDye 800CW-Epidermal growth factor PMID: 20641801 Ref: (111)In-BZ-Diethylenetriaminepentaacetic acid-ZEGFR:1907 PMID: 20641849 Ref: (177)Lu-Labeled humanized monoclonal antibody against human epidermal growth factor receptor 2 PMID: 20641866 Ref: Cy5.5-Epidermal growth factor PMID: 20641899 Ref: (111)In-1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide-Affibody ZHER2:2395-Cys PMID: 20641906 Ref: (99m)Tc-Mercaptoacetyl-Ser-Ser-Ser-Affibody ZHER2:342 PMID: 20641924 Ref: (99m)Tc-Mercaptoacetyl-Gly-Gly-Gly-Affibody ZHER2:342 PMID: 20641926 Ref: (99m)Tc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342 PMID: 20641930 Ref: (125)I-Labeled anti-epidermal growth factor receptor human Fab antibody fragment PMID: 20642017 Ref: Alexa Fluor 750-ZHER2:342 Affibody PMID: 20662137 Ref: DY-682-Albumin-binding domain-fused-ZHER2:342 Affibody PMID: 20845546 Ref: IRDye 800-Anti-epidermal growth factor receptor Affibody PMID: 20845547 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-panitumumab PMID: 20945561 Ref: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-synthetic HER2 specific Affibody ZHER2:342-pep2 PMID: 21086574 Ref: (86)Y-CHX-A''-Diethylenetriamine pentaacetic acid-cetuximab PMID: 21086575 Ref: [(99m)Tc(CO)3](+)-Labeled anti-epidermal growth factor receptor (HER2) affibody ZHER2:342 with a hexa-histidine tag (H6) on the N-terminal PMID: 21290629 Ref: [(99m)Tc(CO)3](+)-Labeled anti-epidermal growth factor receptor (HER2) affibody ZHER2:342 with a tri-(histidine-glutamate) peptide tag (HE)3 on the N-terminal PMID: 21290630 Ref: [(99m)Tc(CO)3](+)-Labeled anti-epidermal growth factor receptor (HER2) affibody ZHER2:342 with a hexa-histidine tag (H6) on the C-terminal PMID: 21290634 Ref: Alexa Fluor 750-albumin-binding domain-fused-(ZHER2:342)2 Affibody PMID: 21491705 Ref: (124)I-Labeled anti-HER2-specific C6.5 diabody PMID: 21834183 Ref: (86)Y-CHX-A''-diethylenetriamine pentaacetic acid-panitumumab PMID: 22171389 Ref: (18)F-1,4,7-Triazacyclononane-1,4,7-triacetic acid-10-maleimidoethylacetamide-Affibody ZHER2:2395 PMID: 22479718 Ref: (89)Zr-Desferrioxamine p-isothiocyanatobenzyl-anti-EGFR nanobody 7D12 PMID: 22696779 Ref: (68)Ga-Desferrioxamine p-isothiocyanatobenzyl-anti-EGFR nanobody 7D12 PMID: 22696780 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-(Gly-Ser-Gly)-Lys-Cys-Cys-Tyr-Ser-Leu PMID: 22787682 Ref: (64)Cu-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-(Gly-Ser-Gly) -Lys-Cys-Cys-Tyr-Ser-Leu PMID: 22787683 Ref: (64)Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-(Gly-Ser-Gly)-Lys-Cys-Cys-Tyr-Ser-Leu PMID: 22787684 Ref: IRDye 800CW-Anti-epidermal growth factor receptor nanobody 7D12 PMID: 22787693 Ref: (99m)Tc(CO)3-Anti-epidermal growth factor receptor nanobody 8B6 PMID: 22787694 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-epidermal growth factor receptor-binding fibronectin domain E13.4.3' PMID: 22896860 Ref: (111)In/(125)I/(99m)Tc-Labeled N-terminus tri-(histidine-glutamate) (HE)3-tagged and N- or C-terminus hexahistidine (H6)-tagged anti-epidermal growth factor receptor Affibody ZHER2:342-C PMID: 22896861 Ref: Cy5.5-Ac-Cys-ZEGFR:1907 PMID: 22973578 Ref: [(111)In-1,4,7-Triazacyclononane,1-glutaric acid-4,7-acetic acid-10-maleimidoethylacetamide-Cys(61)]-Affibody ZHER2:2395 PMID: 22993871 Ref: (111)In-2-(4,7,10-Tris(carboxymethyl)-1,4,7,10-tetracyclododecan-1-yl)pentanedioi c acid-Trastuzumab PMID: 22993872 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-human serum albumin-Ac-Cys-ZEGFR:1907 PMID: 23035309 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidethylacetamide-Ac-Cys-ZEGFR:1907 PMID: 23035311 Ref: QD800-Polyethylene glycol-Cys-ZHER2:342 Affibody PMID: 23101053 Ref: ZHER2:342 Affibody-polyethylene glycol-superparamagnetic iron oxide nanoparticles PMID: 23101054 Ref: N-[2-(4-[(18)F]Fluorobenzamido)ethyl]maleimide-Cys-ZEGFR:1907 PMID: 23136679 Ref: (177)Lu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-human serum albumin-Ac-Cys-ZEGFR:1907 PMID: 23166961 Ref: Cy5.5-8-Amino-octanoic acid-Ser-Cys-Pro-Pro-Trp-Gln-Glu-Trp-His-Asn-Phe-Met-Pro-Phe-NH2 PMID: 23166962 Ref: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-HER2-specific Affibody ZHER2:2891 PMID: 23256220 Ref: N(epsilon)-(3-[(131)I]Iodobenzoyl)-Lys(5)-N(alpha)-maleimido-Gly(1)-GEEEK-anti-HE R2 nanobody 5F7GGC PMID: 23556153 Ref: QD800-Anti-epidermal growth factor receptor monoclonal antibody nanoparticles PMID: 23586108 Ref: IRDye 800-albumin-binding domain-fused-ZHER2:342 Affibody PMID: 23785735 |
Ref: Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers. PMID: 15480783 Ref: COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? PMID: 15589595 Ref: Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. PMID: 15632176 Ref: New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. PMID: 15655420 Ref: T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. PMID: 15659244 Ref: Her-2/neu over-expression correlates with more advanced disease in Iranian colorectal cancer patients. PMID: 15735564 Ref: Quercetin decreases the expression of ErbB2 and ErbB3 proteins in HT-29 human colon cancer cells. PMID: 15741050 Ref: Insulin in aging and cancer: antidiabetic drug Diabenol as geroprotector and anticarcinogen. PMID: 15743682 Ref: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. PMID: 15753357 Ref: (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. PMID: 15814656 Ref: Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist. PMID: 15816539 Ref: Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. PMID: 15841378 Ref: Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells. PMID: 15888451 Ref: HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. PMID: 15899817 Ref: [Study on the prognostic factors of colorectal cancer after radical resection and on suggested model for prediction]. PMID: 15941514 Ref: Expression of p53, DCC, and HER-2/neu in mucinous carcinoma of the breast. PMID: 15960065 Ref: Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. PMID: 15994962 Ref: EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. PMID: 16053920 Ref: [Monoclonal antibody against G3BP: preparation, characterization and its application in analysis of human tumors]. PMID: 16091175 Ref: The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. PMID: 16100458 Ref: Potential use of COX-2-aromatase inhibitor combinations in breast cancer. PMID: 16100520 Ref: Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells. PMID: 16127743 Ref: Establishment and characterization of a human colonic mucinous carcinoma cell line with predominant goblet-cell differentiation from liver metastasis. PMID: 16143030 Ref: Monoclonal antibody therapy of cancer. PMID: 16151408 Ref: Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. PMID: 16199534 Ref: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. PMID: 16244586 Ref: Potential diagnostic utility of CDX-2 immunophenotyping in extramammary Paget's disease. PMID: 16280663 Ref: Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. PMID: 16302076 Ref: Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer. PMID: 16334444 Ref: Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. PMID: 16336751 Ref: Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. PMID: 16379552 Ref: EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. PMID: 16416603 |
Ref: Immunogenic HER-2/neu peptides as tumor vaccines. PMID: 15948002 Ref: Somatic mutations of the ERBB4 kinase domain in human cancers. PMID: 16187281 Ref: Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. PMID: 16376301 Ref: Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases. PMID: 16391868 Ref: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. PMID: 16397024 Ref: Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. PMID: 16397255 Ref: HER 2/neu protein expression in colorectal cancer. PMID: 16681853 Ref: Development of antibodies and chimeric molecules for cancer immunotherapy. PMID: 16730262 Ref: Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. PMID: 16740703 Ref: Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. PMID: 16803682 Ref: Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines. PMID: 17059835 Ref: Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. PMID: 17189393 Ref: Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates. PMID: 17189415 Ref: Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance. PMID: 17219742 |
Ref: HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. PMID: 16882699 Ref: HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. PMID: 16947041 Ref: Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. PMID: 17060407 Ref: Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer. PMID: 17119985 Ref: Identification of differentially expressed genes involved in the formation of multicellular tumor spheroids by HT-29 colon carcinoma cells. PMID: 17164780 Ref: A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. PMID: 17234777 Ref: Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. PMID: 17234795 Ref: Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. PMID: 17250463 Ref: Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. PMID: 17310381 Ref: Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. PMID: 17342325 Ref: Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. PMID: 17505009 Ref: The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. PMID: 17593628 Ref: Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. PMID: 17674041 Ref: [Protein overexpression and gene copy number of EGFR and HER2 in colorectal carcinoma]. PMID: 17845756 Ref: Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. PMID: 17893568 Ref: Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. PMID: 18084614 Ref: Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. PMID: 18220746 Ref: Clinico-Pathological and Prognostic Significance of p53, Bcl-2 and Her-2/neu Protein Markers in Colorectal Cancer Using Tissue Microarray. PMID: 18839030 |
Ref: Prostanoid receptor EP1 expression in breast cancer. PMID: 17906615 Ref: Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). PMID: 18158620 Ref: [Future directions of anticancer drug development in Japan]. PMID: 18281781 Ref: Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. PMID: 18326857 Ref: Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. PMID: 18413824 Ref: Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. PMID: 18472966 Ref: Comparison of delphinidin, quercetin and (-)-epigallocatechin-3-gallate as inhibitors of the EGFR and the ErbB2 receptor phosphorylation. PMID: 18618485 Ref: Does hyaluronic acid stimulate tumor growth after endoscopic mucosal resection? PMID: 18637056 Ref: The expression of cytoskeleton regulatory protein Mena in colorectal lesions. PMID: 18758639 Ref: Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. PMID: 18922903 Ref: Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates the growth of breast cancer. PMID: 18926695 Ref: The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. PMID: 18929150 Ref: ErbB antagonists patenting: "playing chess with cancer". PMID: 19075865 |
Ref: Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. PMID: 18931700 Ref: An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. PMID: 18989354 Ref: Loss of EphA2 receptor tyrosine kinase reduces ApcMin/+ tumorigenesis. PMID: 19089910 Ref: Lessons learned from independent central review. PMID: 19101138 Ref: Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. PMID: 19111388 Ref: Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? PMID: 19118499 Ref: A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. PMID: 19147770 Ref: Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. PMID: 19324279 Ref: Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. PMID: 19331154 Ref: Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. PMID: 19340455 Ref: Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization. PMID: 19368728 Ref: ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. PMID: 19390858 Ref: Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. PMID: 19412098 Ref: ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases. PMID: 19443355 Ref: Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway. PMID: 19472191 Ref: Old disease, new targets--part-I, solid malignancies. PMID: 19534378 Ref: Mechanisms of resistance to ionizing radiation in rectal cancer. PMID: 19580431 Ref: Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. PMID: 19581734 Ref: Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. PMID: 19609239 Ref: Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. PMID: 19690388 Ref: Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. PMID: 19691111 Ref: A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. PMID: 19723649 Ref: Inhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis. PMID: 19754954 Ref: [Construction and identification of CerbB-2 siRNA expression plasmid and its transfer into human colon cancer cell lines HT-29]. PMID: 19778814 Ref: Oncology nursing in a new era: optimizing treatment with bevacizumab. PMID: 19793713 Ref: Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer. PMID: 19797898 |
Ref: Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial. PMID: 19396400 Ref: The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. PMID: 19876926 Ref: Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells. PMID: 20056314 Ref: Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. PMID: 20056651 Ref: Mechanisms of resistance to HER family targeting antibodies. PMID: 20064507 Ref: Foxp3 expression in p53-dependent DNA damage responses. PMID: 20075077 Ref: Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. PMID: 20175926 Ref: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. PMID: 20179677 Ref: Neoadjuvant immunotherapy enhances radiosensitivity through natural killer cell activation. PMID: 20187795 Ref: Predictive biomarker validation in practice: lessons from real trials. PMID: 20392785 Ref: Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. PMID: 20413299 Ref: Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. PMID: 20530441 Ref: Integrating molecular diagnostics into anticancer drug discovery. PMID: 20531274 Ref: Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression. PMID: 20558745 Ref: An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models. PMID: 20569491 Ref: Significance of integrin alphavbeta5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. PMID: 20626753 Ref: Autoproteolysis of the SEA module of rMuc3 C-terminal domain modulates its functional composition. PMID: 20727344 Ref: Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. PMID: 20798912 Ref: The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. PMID: 20811704 Ref: Induction of apoptosis by 5,7-dihydroxy-8-nitrochrysin in breast cancer cells: the role of reactive oxygen species and Akt. PMID: 20878083 Ref: A gene expression signature for chemoradiosensitivity of colorectal cancer cells. PMID: 20970032 Ref: Expression of HER2 in colorectal cancer does not correlate with prognosis. PMID: 21206005 Ref: Thrombopoietin receptor levels in tumor cell lines and primary tumors. PMID: 21318160 Ref: The EGFR R521K polymorphism influences the risk to develop colorectal cancer. PMID: 21896992 Ref: Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. PMID: 23074401 |
Ref: KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. PMID: 20563851 Ref: EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. PMID: 20824716 Ref: EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. PMID: 21109951 Ref: Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy. PMID: 21255939 Ref: [Recent results of research on cancer of the colon, gastric cancer, sarcoma and bronchial carcinoma]. PMID: 21271476 Ref: Conjugated polymer loaded nanospheres with surface functionalization for simultaneous discrimination of different live cancer cells under single wavelength excitation. PMID: 21351748 Ref: Hunk is required for HER2/neu-induced mammary tumorigenesis. PMID: 21393859 Ref: The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. PMID: 21464044 Ref: beta-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis. PMID: 21538055 Ref: [Standardization of evaluation for target molecule in cancer therapy]. PMID: 21566428 Ref: Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. PMID: 21653830 Ref: Human epidermal growth factor receptor-2 and topoisomerase II alpha expressions in rectal cancer. PMID: 21661396 Ref: Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. PMID: 21708009 Ref: Function of erbB receptors and DNA-PKcs on phosphorylation of cytoplasmic and nuclear Akt at S473 induced by erbB1 ligand and ionizing radiation. PMID: 21723633 Ref: Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway. PMID: 21782788 Ref: The role of neuregulin4 and HER4 in gastrointestinal malignant lymphoma. PMID: 21805036 Ref: A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. PMID: 21807638 Ref: Targeted therapies for gastric cancer: current status. PMID: 21812503 Ref: Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERalpha-positive breast cancer. PMID: 21821674 Ref: Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. PMID: 21859497 Ref: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. PMID: 21900593 Ref: Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. PMID: 21949247 Ref: Ileal metastasis of breast cancer in a patient with a BRCA2 gene mutation: report of a case. PMID: 21969203 Ref: Synchronous breast cancers with different morphologic and molecular phenotypes occurring in Lynch syndrome: what does the heterogeneity imply? PMID: 21997695 Ref: American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. PMID: 22070864 Ref: Case report and literature review: Metastatic lobular carcinoma of the breast an unusual presentation. PMID: 22096760 Ref: Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. PMID: 22199994 Ref: HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. PMID: 22586650 Ref: A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. PMID: 22586653 Ref: Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond. PMID: 23480583 |
Ref: Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. PMID: 21652149 Ref: Adjuvant trials of targeted agents: the newest battleground in the war on cancer. PMID: 21818704 Ref: Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients. PMID: 21989899 Ref: Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. PMID: 22048151 Ref: Expression of SPRR3 is associated with tumor cell proliferation in less advanced stages of breast cancer. PMID: 22076481 Ref: RNAi-mediated ERBB2 gene knockdown sensitizes human colorectal cancer cells to radiation. PMID: 22200761 Ref: The "HER2-PI3K/Akt-FASN Axis" regulated malignant phenotype of colorectal cancer cells. PMID: 22218925 Ref: Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract. PMID: 22229849 Ref: Biomarkers for antitumor activity of bevacizumab in gastric cancer models. PMID: 22273502 Ref: Cell cycle proteins predict recurrence in stage II and III colon cancer. PMID: 22311118 Ref: Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. PMID: 22371427 Ref: Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. PMID: 22427198 Ref: [Biological behaviour of colon cancer cells transfected with C-erbB2 shRNA plasmid]. PMID: 22482406 Ref: MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. PMID: 22581829 Ref: The relationship between the stromal mast cell number, microvessel density, c-erbB-2 staining and survival and prognostic factors in colorectal carcinoma. PMID: 22627628 Ref: Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. PMID: 22751462 Ref: Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cells. PMID: 22788833 Ref: KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. PMID: 22797671 Ref: Comprehensive molecular characterization of human colon and rectal cancer. PMID: 22810696 Ref: Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. PMID: 22845480 Ref: Molecular diagnosis on tissues and cells: how it affects training and will affect practice in the future. PMID: 22846108 Ref: A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PMID: 22860045 Ref: Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway. PMID: 22860766 Ref: [Therapeutic monoclonal antibodies in oncology]. PMID: 22863361 Ref: Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. PMID: 22899293 Ref: Anti-HER-2 anti-CD3 bi-specific antibodies inhibit growth of HCT-116 colorectal carcinoma cells in vitro and in vivo. PMID: 22938461 Ref: Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. PMID: 22952420 Ref: Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location. PMID: 22956806 Ref: Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. PMID: 22984537 Ref: Redirecting gene-modified T cells toward various cancer types using tagged antibodies. PMID: 23032741 Ref: Circulating tumor cells in lung cancer. PMID: 23207444 Ref: Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. PMID: 23213241 Ref: Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. PMID: 23220854 Ref: Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PMID: 23226389 Ref: alpha-Mangostin Reduced ER Stress-mediated Tumor Growth through Autophagy Activation. PMID: 23396851 Ref: Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. PMID: 23464465 |
Ref: Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. PMID: 22535374 Ref: Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. PMID: 22973964 Ref: Comprehensive fluorogenic derivatization-liquid chromatography/tandem mass spectrometry proteomic analysis of colorectal cancer cell to identify biomarker candidate. PMID: 22991145 Ref: Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer. PMID: 23180020 Ref: Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells. PMID: 23184679 Ref: HER3 overexpression and survival in solid tumors: a meta-analysis. PMID: 23221996 Ref: Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. PMID: 23281932 Ref: miR-214 and hypoxia down-regulate Necl-2/CADM1 and enhance ErbB2/ErbB3 signaling. PMID: 23301758 Ref: Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. PMID: 23316969 Ref: Chromosome 16q loss--a genetic key to the understanding of breast carcinogenesis. PMID: 23348384 Ref: Identification of ROS1 rearrangement in gastric adenocarcinoma. PMID: 23400546 Ref: Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. PMID: 23471238 Ref: Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. PMID: 23517721 Ref: Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. PMID: 23518595 Ref: The expression of Egfl7 in human normal tissues and epithelial tumors. PMID: 23558933 Ref: Designing transformative clinical trials in the cancer genome era. PMID: 23589555 Ref: Clinical role of HER-2/neu expression in colorectal cancer. PMID: 23613394 Ref: 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint. PMID: 23632482 Ref: Simultaneous phenotypic and genetic characterization of single circulating tumor cells from colon cancer patients. PMID: 23653253 Ref: Companion biomarkers: paving the pathway to personalized treatment for cancer. PMID: 23656699 Ref: Rare epithelial tumors arising in or near the ovary: a review of the risk factors, presentation, and future treatment direction for ovarian clear cell and mucinous carcinoma. PMID: 23714502 Ref: Loss of fatty acid synthase inhibits the "HER2-PI3K/Akt axis" activity and malignant phenotype of Caco-2 cells. PMID: 23725225 Ref: Induction of apoptosis and the regulation of ErbB signaling by laminarin in HT-29 human colon cancer cells. PMID: 23739740 Ref: Molecular classification of colorectal cancer: a dream that can become a reality. PMID: 23771065 Ref: Targeting cancer with a bi-functional peptide: in vitro and in vivo results. PMID: 23812212 Ref: Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. PMID: 23852390 Ref: [Expression of molecular markers detected by immunohistochemistry and risk of lymph node metastasis in stage T1 and T2 colorecrectal cancers]. PMID: 23985256 Ref: Src plays a key role in ADAM28 expression in v-src-transformed epithelial cells and human carcinoma cells. PMID: 24007880 Ref: Helicobacter pylori: gastric cancer and extragastric malignancies - clinical aspects. PMID: 24011244 Ref: The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. PMID: 24050852 Ref: Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. PMID: 24086949 Ref: HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. PMID: 24146218 Ref: Multigene assays in metastatic colorectal cancer. PMID: 24158971 Ref: Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. PMID: 24196786 Ref: Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PMID: 24205104 Ref: [Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases]. PMID: 24273914 Ref: HER2 and immunotherapy using monoclonal antibodies in colorectal cancer. PMID: 24283833 Ref: Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. PMID: 24356468 Ref: The role of microRNA-200 in progression of human colorectal and breast cancer. PMID: 24376848 Ref: Synchronous rectal and gastric cancer in a fighter pilot: aeromedical concerns. PMID: 24426647 |
Ref: Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. PMID: 23493335 Ref: Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. PMID: 23568716 Ref: Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. PMID: 23817974 Ref: Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. PMID: 23852704 Ref: Functions and regulation of MUC13 mucin in colon cancer cells. PMID: 24097071 Ref: AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. PMID: 24170546 Ref: The ErbB/HER family of protein-tyrosine kinases and cancer. PMID: 24269963 Ref: CHIP/Stub1 functions as a tumor suppressor and represses NF-kappaB-mediated signaling in colorectal cancer. PMID: 24302614 Ref: The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. PMID: 24371223 Ref: The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. PMID: 24516696 Ref: A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. PMID: 24643470 Ref: Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. PMID: 24668895 Ref: Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PMID: 24676216 Ref: Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. PMID: 24685132 Ref: Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. PMID: 24733427 Ref: [Circulating tumor cells: a new challenge for laboratory medicine]. PMID: 24736136 Ref: Characterization of proapoptotic compounds from the bark of Garcinia oblongifolia. PMID: 24754786 Ref: Death decoy receptor overexpression and increased malignancy risk in colorectal cancer. PMID: 24764685 Ref: Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. PMID: 24771148 Ref: EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules. PMID: 24792576 Ref: Regulation and roles of bicarbonate transporters in cancer. PMID: 24795638 Ref: MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine. PMID: 24807584 Ref: Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer. PMID: 24817953 Ref: Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis. PMID: 24819100 Ref: The prognostic value of the Na(+)/ H(+) exchanger regulatory factor 1 (NHERF1) protein in cancer. PMID: 24878819 Ref: HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PMID: 24879338 Ref: Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients. PMID: 24910416 Ref: ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. PMID: 24928736 Ref: HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound. PMID: 24946763 Ref: Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. PMID: 24947902 Ref: ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. PMID: 24970817 Ref: STED super-resolution microscopy of clinical paraffin-embedded human rectal cancer tissue. PMID: 25025184 Ref: Therapy of peritoneally disseminated colon cancer by TAP-deficient embryonic stem cell-derived macrophages in allogeneic recipients. PMID: 25031460 Ref: HER2 in solid tumors: more than 10 years under the microscope; where are we now? PMID: 25052756 Ref: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. PMID: 25057166 Ref: The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies. PMID: 25077923 Ref: Lack of effects of HER-2/neu on prognosis in colorectal cancer: a meta-analysis. PMID: 25081663 Ref: Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PMID: 25090459 Ref: Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas. PMID: 25120833 Ref: Overexpression of alpha2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis. PMID: 25142811 Ref: HER2/neu testing in primary colorectal carcinoma. PMID: 25211663 Ref: Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo. PMID: 25242665 Ref: Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. PMID: 25287912 Ref: Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. PMID: 25293556 Ref: Molecular targeting to treat gastric cancer. PMID: 25320512 Ref: Somatic mutations of the HER2 in metastatic breast cancer. PMID: 25326805 Ref: Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. PMID: 25389372 Ref: Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer. PMID: 25416285 Ref: The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. PMID: 25474137 Ref: The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. PMID: 25525412 Ref: [The differences between three distinct locations of colorectal cancers based on clinicopathological characteristics and molecular features]. PMID: 25619220 |
Ref: Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. PMID: 24292678 Ref: Personalised cancer medicine. PMID: 24789362 Ref: 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. PMID: 25238789 Ref: Tissue-specific selection of optimal reference genes for expression analysis of anti-cancer drug-related genes in tumor samples using quantitative real-time RT-PCR. PMID: 25445497 Ref: A 21-year-old patient with a HER2-positive colorectal cancer. PMID: 25447849 Ref: Biomarkers for personalized oncology: recent advances and future challenges. PMID: 25468140 Ref: Examination of HER3 targeting in cancer using monoclonal antibodies. PMID: 25564668 Ref: HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver. PMID: 25601452 Ref: HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value. PMID: 25739551 Ref: Hunk/Mak-v is a negative regulator of intestinal cell proliferation. PMID: 25881306 Ref: A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol. PMID: 25885574 Ref: Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients. PMID: 25889931 Ref: Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond. PMID: 25924988 Ref: Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. PMID: 25973297 Ref: Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. PMID: 25993166 Ref: Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays. PMID: 26026893 Ref: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. PMID: 26030179 Ref: Gene expression profiling of laterally spreading tumors. PMID: 26048755 Ref: Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population. PMID: 26077004 Ref: Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. PMID: 26077270 Ref: Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer. PMID: 26077887 Ref: Genetic mutations in human rectal cancers detected by targeted sequencing. PMID: 26134512 Ref: Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. PMID: 26186012 Ref: ERBB2 emerges as a new target for colorectal cancer. PMID: 26243861 Ref: HER2 activating mutations are targets for colorectal cancer treatment. PMID: 26243863 Ref: Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. PMID: 26244165 Ref: Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. PMID: 26258407 Ref: Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. PMID: 26276145 Ref: Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. PMID: 26287187 Ref: Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. PMID: 26317899 Ref: Isolation and characterization of circulating micro(nano)vesicles in the plasma of colorectal cancer patients and their interactions with tumor cells. PMID: 26324403 Ref: Clonal origins and parallel evolution of regionally synchronous colorectal adenoma and carcinoma. PMID: 26336987 Ref: Renal toxicity of anticancer agents targeting HER2 and EGFR. PMID: 26341657 Ref: Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. PMID: 26384318 Ref: The genomic landscape of response to EGFR blockade in colorectal cancer. PMID: 26416732 Ref: Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues. PMID: 26435392 Ref: Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. PMID: 26449765 Ref: Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. PMID: 26452385 Ref: [Molecular phenotypes of colorectal cancer is critical in clinical individual treatment]. PMID: 26499143 Ref: The use of combinations of monoclonal antibodies in clinical oncology. PMID: 26547132 Ref: Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. PMID: 26553611 Ref: Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors. PMID: 26554380 Ref: Overcoming Resistance to Targeted Therapies in Cancer. PMID: 26615134 Ref: Survey of HER2-neu Expression in Colonic Adenocarcinoma in the West of Iran. PMID: 26625779 Ref: [A Case of a Submucosal Tumor-Like Gastric Cancer That Needed to Be Distinguished from Gastric Metastasis of Rectal Cancer]. PMID: 26805234 Ref: [Companion Diagnostics for Solid Tumors]. PMID: 26995877 |
Ref: Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. PMID: 26001389 Ref: Pertuzumab in gastrointestinal cancer. PMID: 26619359 Ref: HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. PMID: 26657506 Ref: Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. PMID: 26660078 Ref: HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. PMID: 26690310 Ref: Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2. PMID: 26709709 Ref: Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins. PMID: 26718323 Ref: MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer. PMID: 26718987 Ref: Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. PMID: 26741147 Ref: Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. PMID: 26797410 Ref: WISP3 is highly expressed in a subset of colorectal carcinomas with a better prognosis. PMID: 26834488 Ref: HER3 expression is correlated to distally located and low-grade colon cancer. PMID: 26863446 Ref: Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. PMID: 26909603 Ref: Human Epidermal Growth Factor Receptor Expression in Colorectal Cancer and Its Relationship with Clinicopathological Characteristics. PMID: 26933478 Ref: Downregulation of epidermal growth factor receptor family receptors and ligands in a mutant K-ras group of patients with colorectal cancer. PMID: 26935861 Ref: BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. PMID: 26991109 Ref: Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/beta-catenin signaling pathway mutations. PMID: 26998897 Ref: Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. PMID: 27010906 Ref: Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. PMID: 27012666 Ref: Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. PMID: 27026198 Ref: Consensus and conflict in invasive micropapillary carcinoma: a case report and review of the literature. PMID: 27034813 Ref: Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. PMID: 27063727 Ref: Theranostic multimodular potential of zinc-doped ferrite-saturated metal-binding protein-loaded novel nanocapsules in cancers. PMID: 27099495 Ref: Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: a meta-analysis. PMID: 27102863 Ref: Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. PMID: 27108243 Ref: Targeting HER2: precision oncology for colorectal cancer. PMID: 27108244 Ref: Mucinous epithelial ovarian carcinoma. PMID: 27141073 Ref: Hsp70 exerts oncogenic activity in the Apc mutant Min mouse model. PMID: 27207671 Ref: Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue. PMID: 27257141 Ref: Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants. PMID: 27260798 Ref: PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study. PMID: 27296289 Ref: Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. PMID: 27332557 Ref: Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. PMID: 27341591 Ref: Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer. PMID: 27373506 Ref: Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). PMID: 27465221 Ref: HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. PMID: 27542243 Ref: Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer. PMID: 27547057 Ref: Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing. PMID: 27568332 Ref: Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. PMID: 27570430 Ref: A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway. PMID: 27581375 Ref: Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials. PMID: 27598201 Ref: Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer. PMID: 27610130 Ref: Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. PMID: 27626067 Ref: How the lab is changing our view of colorectal cancer. PMID: 27647226 Ref: A perspective on anti-EGFR therapies targeting triple-negative breast cancer. PMID: 27648353 Ref: HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. PMID: 27672288 Ref: Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. PMID: 27682134 Ref: The prospect of patritumab for treating non-small cell lung cancer. PMID: 27744717 Ref: Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country. PMID: 27821098 Ref: A case report of chylous ascites after gastric bypass for morbid obesity. PMID: 27846453 Ref: Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) and Microsatellite Instability in Patients with Colorectal Cancer and Its Clinical Features. PMID: 27889996 Ref: Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. PMID: 28007036 Ref: Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. PMID: 28050146 Ref: [A Case of Metastatic Colon Cancer Dramatically Affected by Anti-EGFR Antibody Therapy]. PMID: 28133136 Ref: [Right Hemi-Colectomy for a Metastatic Transverse Colon Tumor from Breast Cancer Following Bilateral Breast Cancer Resection - A Case Report]. PMID: 28133217 Ref: [A Case of Metastatic Colorectal Cancer with HER2 Overexpression/Amplification]. PMID: 28133304 |
Ref: Structure-based design of peptides against HER2 with cytotoxicity on colon cancer. PMID: 27068253 Ref: Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. PMID: 27737436 Ref: Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer. PMID: 27887848 Ref: Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer. PMID: 28006840 Ref: Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. PMID: 28032592 Ref: Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. PMID: 28040715 Ref: Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. PMID: 28055269 Ref: Translating genomic profiling to gastrointestinal cancer treatment. PMID: 28067073 Ref: Multi-institutional Nomogram Predicting Survival Free From Salvage Whole Brain Radiation After Radiosurgery in Patients With Brain Metastases. PMID: 28068233 Ref: High levels of serum platelet-derived growth factor-AA and human epidermal growth factor receptor-2 are predictors of colorectal cancer liver metastasis. PMID: 28275303 Ref: Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. PMID: 28280626 Ref: HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. PMID: 28363756 Ref: Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1. PMID: 28366103 Ref: Profiling Differential Responses to Pan-HER Inhibition. PMID: 28373301 Ref: Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer. PMID: 28412781 Ref: Risk factors for brain metastases in patients with metastatic colorectal cancer. PMID: 28447565 Ref: Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. PMID: 28473715 Ref: Trans-scirpusin A showed antitumor effects via autophagy activation and apoptosis induction of colorectal cancer cells. PMID: 28489607 Ref: What We Know About Stage II and III Colon Cancer: It's Still Not Enough. PMID: 28504299 Ref: Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients. PMID: 28570747 Ref: Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective. PMID: 28581874 Ref: Next-generation sequencing traces human induced pluripotent stem cell lines clonally generated from heterogeneous cancer tissue. PMID: 28596815 Ref: Genomic Profiling of Small-Bowel Adenocarcinoma. PMID: 28617917 Ref: Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. PMID: 28629479 Ref: Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. PMID: 28683746 Ref: Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. PMID: 28736627 Ref: Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. PMID: 28736628 Ref: Primary and acquired resistance to biologic therapies in gastrointestinal cancers. PMID: 28736637 Ref: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer. PMID: 28764718 Ref: Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer. PMID: 28784859 Ref: Recent developments in the treatment of metastatic colorectal cancer. PMID: 28794806 Ref: Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy. PMID: 28821938 Ref: Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care. PMID: 28978093 Ref: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. PMID: 29024937 Ref: PUMA mediates the anti-cancer effect of osimertinib in colon cancer cells. PMID: 29138581 Ref: Establishment of H2Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer. PMID: 29172998 Ref: Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. PMID: 29212173 Ref: Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. PMID: 29285234 Ref: Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. PMID: 29312543 Ref: [A Case of Synchronous Quadruple Cancers Treated with Neoadjuvant Chemotherapy Followed by Surgery]. PMID: 29394804 Ref: Biomarker-driven and molecular targeted therapies for colorectal cancers. PMID: 30262397 |
Ref: Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. PMID: 29195807 Ref: Proximal Aberrant Crypt Foci Associate with Synchronous Neoplasia and Are Primed for Neoplastic Progression. PMID: 29222172 Ref: Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. PMID: 29242316 Ref: Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. PMID: 29254887 Ref: Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer. PMID: 29315012 Ref: BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. PMID: 29326440 Ref: Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer. PMID: 29330210 Ref: Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. PMID: 29338072 Ref: Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer. PMID: 29344282 Ref: Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer. PMID: 29361822 Ref: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. PMID: 29387480 Ref: The importance of EGFR as a biomarker in molecular apocrine breast cancer. PMID: 29409930 Ref: Copy number profiles of paired primary and metastatic colorectal cancers. PMID: 29423054 Ref: Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. PMID: 29438965 Ref: First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. PMID: 29470838 Ref: Clinical Trials and Progress in Metastatic Colon Cancer. PMID: 29496094 Ref: Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells. PMID: 29541416 Ref: Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. PMID: 29589315 Ref: Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. PMID: 29659677 Ref: Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. PMID: 29665843 Ref: The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells. PMID: 29684854 Ref: Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. PMID: 29718453 Ref: Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology. PMID: 29740162 Ref: Promising New Agents for Colorectal Cancer. PMID: 29752549 Ref: Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. PMID: 29755687 Ref: The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. PMID: 29776953 Ref: Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation. PMID: 29788391 Ref: Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. PMID: 29844865 Ref: Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. PMID: 29854313 Ref: Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. PMID: 29855806 Ref: Correlated non-nuclear COX2 and low HER2 expression confers a good prognosis in colorectal cancer. PMID: 29873317 Ref: Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor. PMID: 29885789 Ref: Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience. PMID: 29985199 Ref: Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. PMID: 29990497 Ref: Targeted therapy for metastatic colorectal cancer. PMID: 30019590 Ref: Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression. PMID: 30045934 Ref: Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability. PMID: 30056083 Ref: HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features. PMID: 30056472 Ref: Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. PMID: 30092682 Ref: HER2: An emerging target in colorectal cancer. PMID: 30100092 Ref: The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. PMID: 30171333 Ref: PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study. PMID: 30189107 Ref: Variability in HER2 expression between primary colorectal cancer and corresponding metastases. PMID: 30203148 Ref: Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. PMID: 30205948 Ref: SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using (125)I-Herceptin. PMID: 30217443 Ref: Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. PMID: 30231342 Ref: High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer. PMID: 30275857 Ref: ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in Early Stage Gallbladder Cancer. PMID: 30304546 Ref: Association between Her2/neu status in colorectal carcinoma and clinicopathological features: a retrospective study using whole - tissue sections. PMID: 30351861 Ref: Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. PMID: 30373904 |